1.2. Analysis.
Comparison 1 Leukotriene Receptor Antagonists (LTRA) + ICS vs. same dose of ICS in SYMPTOMATIC patients, Outcome 2 Patients with exacerbations requiring systemic steroids with licensed AL doses at 4 to 16 weeks.
Comparison 1 Leukotriene Receptor Antagonists (LTRA) + ICS vs. same dose of ICS in SYMPTOMATIC patients, Outcome 2 Patients with exacerbations requiring systemic steroids with licensed AL doses at 4 to 16 weeks.